Skip to content
DataLookout
Menu

ROOTNCT07913347

Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study)

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Safety and tolerability of MGT-006 (adverse events, adverse reactions)
Timeframe: Phase 1b: From first administration of study medication(MGT-006 or antibiotics) through four weeks after completion of MGT-006 treatment.

Secondary (2)

Engraftment of MGT-006-derived gut microbiota by 12 weeks after the start of MGT-006 administration
The following efficacy endpoints at 8 weeks after the start of MGT-006 administration based on central imaging assessment: (1) Clinical remission rate (2) Clinical response rate (3) Endoscopic improvement rate

Arms and interventions

Phase 1b: MGT-006 Without Antibiotic PretreatmentExperimental

Participants receive no antibiotic pretreatment. MGT-006 is administered orally at four capsules per dose, three times daily before meals, for 56 days. Participants are observed for four weeks after completion of MGT-006 treatment.

Phase 1b: Vancomycin Pretreatment Followed by MGT-006Experimental

Participants receive oral vancomycin hydrochloride at a total daily dose of 500 mg (as vancomycin), divided into four daily administrations, for five days. MGT-006 is then administered orally at four capsules per dose, three times daily before meals, for 56 days, followed by four weeks of observation. MGT-006 starts within two days after completion of vancomycin pretreatment.

Phase 1b: AFM Pretreatment Followed by MGT-006Experimental

Subjects allocated to the AFM group will receive pretreatment antibiotics for 5 days after final registration. Amoxicillin hydrate 1500 mg/day (as amoxicillin), fosfomycin calcium hydrate 3000 mg/day (as fosfomycin), and metronidazole 750 mg/day will be orally administered three times a day for 5 days.

Phase 2a: High-Dose MGT-006Experimental

The dosage/administration and duration of treatment are subject to change depending on the Phase 1b progress.

Phase 2a: Medium-Dose MGT-006Experimental

The dosage/administration and duration of treatment are subject to change depending on the Phase 1b progress.

Phase 2a: Low-Dose MGT-006Experimental

The dosage/administration and duration of treatment are subject to change depending on the Phase 1b progress.

Drugs: MGT-006, Vancomycin hydrochloride, Amoxicillin hydrate/ Fosfomycin calcium hydrate/ Metronidazole

Sites

12 sites in 2 countries

Japan 9, United States 3